SavedAdd your journal

Journals / Şişli Etfal Hastanesi Tıp Bülteni / 2012 / Cilt: 46 - Sayı: 3

Long term renal replacement and plasmapheresis therapy in case of hemolytic uremic syndrome: intensive care unit experience

Hemolitik üremik sendrom olgusunda uzun süreli renal replasman ve plazmaferez tedavisi: Yoğun bakım ünitesi deneyimi

Ozan GÖKUŞ
Hacer Şebnem TÜRK
Tolga TOTOZ
Oya ÜNSAL
Gül ÖZÇELİK ŞUMLU
Sibel OBA
Pages
148–152
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

By our case; we aimed to discuss the intensive support treatment, longterm renal replacement treatment and plasmatherapy in HUS.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Hemolytic uremic syndrome (HUS) is a clinical situation which is characterized by hemolytic anemia, thrombocytopenia and acute renal failure.
📊
Key Findings & Data:Typical HUS is the most frequent form of HUS in children, occurs due to Shigatoxin and %90 presents after diarrhea and upper airway infection.
💡
Conclusion & Impact:By our case; we aimed to discuss the intensive support treatment, longterm renal replacement treatment and plasmatherapy in HUS.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Hemolytic uremic syndrome (HUS) is a clinical situation which is characterized by hemolytic anemia, thrombocytopenia and acute renal failure. This syndrome is one of the most common causes of acute renal failure in infants and children. There is two types of HUS. Typical HUS is the most frequent form of HUS in children, occurs due to Shigatoxin and %90 presents after diarrhea and upper airway infection. Atypical HUS is a primary disease due to a disorder in complement alternative pathway regulation and known as non Shigatoxin- HUS. 5-10% of HUS in children is atypical HUS and 20% of these cases have extra renal manifestations. Rates of deterioration to the end-stage renal failure and mortality are high at first episode. Normalizing hipertansion, appropriate fluid and electrolyte therapy, early dialysis and nutritional support decreases the mortality. Nowadays, intensive plasmatherapy is the first line treatment. By our case; we aimed to discuss the intensive support treatment, longterm renal replacement treatment and plasmatherapy in HUS.

Özet

Hemolitik üremik sendrom (HÜS); hemolitik anemi, trombositopeni ve akut renal yetmezlik ile karakterize klinik bir tablodur. İnfant ve çocuklarda akut böbrek yetmezliğinin en sık nedenlerinden biridir. HÜS’ün iki tipi mevcuttur. Tipik HÜS; Shigatoksine bağlı olarak gelişen, %90 diyare veya üst solunum yolu enfeksiyonunu takiben ortaya çıkan ve çocuklarda en sık görülen formdur. Atipik HÜS, kompleman alternatif yolunun regülasyonundaki bozukluğa bağlı gelişen primer hastalıktır ve non Shigatoksin-HÜS olarak da bilinir. HÜS gelişen çocukların %5-10’u atipik HÜS’dür ve bu olguların %20’sine ekstra-renal hastalıklar eşlik eder. İlk atakta son dönem böbrek yetmezliği gelişme ve mortalite oranları yüksektir. Hipertansiyonun hemen düzeltilmesi, uygun elektrolit ve sıvı tedavisi, erken diyaliz ve nütrisyonel destek mortaliteyi azaltır. Günümüzde, yoğun plazmaterapi en etkin tedavi yöntemidir. Biz de olgumuz eşliğinde HÜS’de yoğun destek tedavisini, plazmaferezi ve uzun süreli renal replasman tedavisini tartışmayı amaçladık.

🔖

Cite This Article

GÖKUŞ, O., TÜRK, H. Ş., TOTOZ, T., ÜNSAL, O., ŞUMLU, G. Ö., OBA, S. (2012). Long term renal replacement and plasmapheresis therapy in case of hemolytic uremic syndrome: intensive care unit experience. Şişli Etfal Hastanesi Tıp Bülteni, Cilt: 46 - Sayı: 3, 148–152. https://ajindex.com/articles/363475

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Bergstein J. Hemolytic Uremic Syndrome. In: Behrman RE, Kliegman RM, Jenson HB (eds). Nelson Textbook of Pediatrics. Philadelphia, Saunders Company, 2000: 1586-7
  2. Halevy D, Radhakrishan J, Markowitz G, et al. Thrombotic microangiopathies. Crit Care Clin 2002; 18: 309-320
  3. Devecioğlu Ö. Kanama ve Pıhtılaşma Bozuklukları. Neyzi O, Ertuğrul T (ed). Pediatri. İstanbul, Nobel Tıp Kitabevleri, 2002: 1083
  4. Loirat C. Post-diarrhea hemolytic uremic syndrome: Clinical aspects. Arch Pediatr 2001; 4: 776-84
  5. Niaudet, Patrick. Clinical manifestations and diagnosis of shigaliketoxin associated hemolytic uremic syndrome in children. Uptodate.com, September 2011
  6. Loirat C, Noris M, Fremeaux-Bacchi V: Complement and the atypical hemolytic uremic syndrome. Pediatr Nephrol 2008; 23:1957-72
  7. Ariceta G, Besbas N, Johnson S, Karpman D, Landau D, Licht C, Loirat C, Pecoraro C, Tylor C, Van De Kar N, Van De Wall J, Zimmerhackl L. Guidelines for the investigation and initial therapy of diarrhea negative haemolytic ureamic syndrome. Pediatr Nephrol 2009; 24:687-96
  8. Taylor CM, Machin S, Wigmore SJ, Goodship TH. Clinical Practice Guidelines for the management of atypical Haemolytic Uraemic Syndrome in the United Kingdom. Br J Haematol 2010; 148:37-47
  9. Loirat C, Garnier A, Sellier-Leclerc AL, Know T. Plasmatherapy in atypical hemolytic uremic syndrome. Semin Thromb Hemost 2010; 36:673-81
  10. Loriat C, Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet Journal of Rare Dıseases 2011; 6:60
  11. Shety KJ, Swick HM, Haworty N. Neurologic involvement in hemolytic uremic syndrome. Ann Neurol 1986; 19: 90-3
  12. Rowe PC, Orrbine E, Wells GA, McLaine PN. Epidemiology of hemolytic uremic syndrome in Canadian children from 1986 to 1988. J Pediatr 1991; 119: 218-24
  13. Kinney JS, Gross TP, Porter CC, Rogers MF, Schonberger LB, Hurwitz ES. Hemolytic uremic syndrome: A population-based study in Washington DC and Baltimore, Maryland. Am J Public Health 1988; 78: 64-5
  14. Mahan JD. Hemolytic uremic syndrome. In: Clinical Pediatric Nephrology. Kher K, Schnaper HW and Makker SP (eds). 2007; 235-44
  15. Bonilla-Félix M. Peritoneal dialysis in the pediatric intensive care unit setting. Perit Dial Int. 2009; 29 Suppl 2: 183-5
  16. Ligth C, Weyersherg A, Heinen S, et al. Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. Am J Kidney Dis 2005; 45: 415